SARS-CoV-2 infection during pregnancy has been associated with poor maternal and neonatal outcomes and placental defects. The placenta, which acts as a physical and immunological barrier at the maternal–fetal interface, is not established until the end of the first trimester. Therefore, localized viral infection of the trophoblast compartment early in gestation could trigger an inflammatory response resulting in altered placental function and consequent suboptimal conditions for fetal growth and development. In this study, we investigated the effect of SARS-CoV-2 infection in early gestation placentae using placenta-derived human trophoblast stem cells (TSCs), a novel in vitro model, and their extravillous trophoblast (EVT) and syncytiotrophoblast (STB) derivatives. SARS-CoV-2 was able to productively replicate in TSC-derived STB and EVT, but not undifferentiated TSCs, which is consistent with the expression of SARS-CoV-2 entry host factors, ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 (transmembrane cellular serine protease) in these cells. In addition, both TSC-derived EVT and STB infected with SARS-CoV-2 elicited an interferon-mediated innate immune response. Combined, these results suggest that placenta-derived TSCs are a robust in vitro model to investigate the effect of SARS-CoV-2 infection in the trophoblast compartment of the early placenta and that SARS-CoV-2 infection in early gestation activates the innate immune response and inflammation pathways. Therefore, placental development could be adversely affected by early SARS-CoV-2 infection by directly infecting the developing differentiated trophoblast compartment, posing a higher risk for poor pregnancy outcomes.
Get full access to this article
View all access options for this article.
References
1.
AlloteyJ, StallingsE, BonetM, YapM, ChatterjeeS, KewT, DebenhamL, LlavallAC, DixitA, et al. (2020). Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ, 370:m3320.
2.
PrabhuM, CaginoK, MatthewsKC, FriedlanderRL, GlynnSM, KubiakJM, YangYJ, ZhaoZ, BaergenRN, et al. (2020). Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG An Int J Obstet, Gynaecol127:1548–1556.
3.
BouachbaA, AlliasF, NadaudB, MassardierJ, MekkiY, Bouscambertuchamp MD, De La FourniereB, HuissoudC, TrecourtA and Collardeau-FrachonS. (2021). Placental lesions and SARS-Cov-2 infection: diffuse placenta damage associated to poor fetal outcome. Placenta, 112:97–104.
4.
RobertsDJ, EdlowAG, RomeroRJ, CoyneCB, TingDT, HornickJL, ZakiSR, Das AdhikariU, SerghidesL, GawSL and MetzTD. (2021). A standardized definition of placental infection by SARS-CoV-2, a consensus statement from the National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development SARS-CoV-2 Placental Infection Workshop. Am J Obstet Gynecol, 225:593.e1–e593.e9.
5.
KotlyarAM, GrechukhinaO, ChenA, PopkhadzeS, GrimshawA, TalO, TaylorHS and TalR. (2021). Vertical transmission of coronavirus disease 2019: a systematic review and meta-analysis. Am J Obstet Gynecol, 224:35–53.e3.
6.
SmithgallMC, Liu-JarinX, Hamele-BenaD, CimicA, MouradM, DebelenkoL and ChenX. (2020). Third-trimester placentas of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive women: histomorphology, including viral immunohistochemistry and in-situ hybridization. Histopathology, 77:994–999.
7.
ShanesED, MithalLB, OteroS, AzadHA, MillerES and GoldsteinJA. (2020). Placental pathology in COVID-19. Am J Clin Pathol, 154:23–32.
8.
HosierH, FarhadianS, MorottiRA, DeshmukhU, Lu-CulliganA, CampbellKH, YasumotoY, VogelsCBF, Casanovas-MassanaA, et al. (2020). SARS-CoV-2 infection of the placenta. medRxiv, 130:4947–4953.
9.
JaiswalN, PuriM, AgarwalK, SinghS, YadavR, TiwaryN, TayalP and VatsB. (2021). COVID-19 as an independent risk factor for subclinical placental dysfunction. Eur J Obstet Gynecol Reprod Biol, 259:7–11.
10.
MenterT, MertzKD, JiangS, ChenH, MonodC, TzankovA, WaldvogelS, SchulzkeSM, HösliI and BruderE. (2021). Placental pathology findings during and after SARS-CoV-2 infection: features of villitis and malperfusion. Pathobiology, 88:69–77.
11.
SchwartzDA, Avvad-PortariE, BabalP, BaldewijnsM, BlombergM, BouachbaA, CamachoJ, Collardeau-FrachonS, ColsonA, et al. (2022). Placental tissue destruction and insufficiency from COVID-19 causes stillbirth and neonatal death from hypoxic-ischemic injury: a study of 68 cases with SARS-CoV-2 placentitis from 12 countries. Arch Pathol Lab Med, 146:660–676.
12.
Garrido-PontnouM, NavarroA, CamachoJ, CrispiF, Alguacil-GuillénM, Moreno-BaróA, Hernandez-LosaJ, SeséM, Ramón y CajalS, et al. (2021). Diffuse trophoblast damage is the hallmark of SARS-CoV-2-associated fetal demise. Mod Pathol, 34:1704–1709.
13.
HusenMF, van der MeerenLE, VerdijkRM, FraaijPLA, van der EijkAA, KoopmansMPG, FreemanL, BogersH, TrietschMD, et al. (2021). Unique severe covid-19 placental signature independent of severity of clinical maternal symptoms. Viruses, 13:1670.
14.
Lu-CulliganA, ChavanAR, VijayakumarP, IrshaidL, CourchaineEM, MilanoKM, TangZ, PopeSD, SongE, et al. (2021). Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med (N Y), 2:591–610.e10.
15.
ShererML, LeiJ, CreisherP, JangM, ReddyR, VoegtlineK, OlsonS, LittlefieldK, ParkH-S, et al. (2020). Dysregulated immunity in SARS-CoV-2 infected pregnant women. medRxiv Preprint Serv Health Sci, 2020:20231373.
16.
PolidoroRB, HaganRS, de Santis SantiagoR and SchmidtNW. (2020). Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol, 11:1626.
17.
SiddiqiHK and MehraMR. (2020). COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Heart Lung Transplant, 39:405–407.
18.
RedlineRW, RavishankarS, BagbyCM, SaabST and ZareiS. (2021). Four major patterns of placental injury: a stepwise guide for understanding and implementing the 2016 Amsterdam Consensus. Mod Pathol, 34:1074–1092.
19.
Arechavaleta-VelascoF, KoiH, Strauss IiiJF and ParryS. (2002). Viral infection of the trophoblast: time to take a serious look at its role in abnormal implantation and placentation?. J Reprod Immunol, 55:113–121.
20.
León-JuárezM, Martínez-CastilloM, González-GarcíaLD, Helguera-RepettoAC, Zaga-ClavellinaV, García-CorderoJ, Flores-PliegoA, Herrera-SalazarA, Vázquez-MartínezER and Reyes-MuñozE. (2017). Cellular and molecular mechanisms of viral infection in the human placenta. Pathog Dis, 75:ftx093.
21.
RacicotK and MorG. (2017). Risks associated with viral infections during pregnancy. J Clin Invest, 127:1591–1599.
22.
KwonJY, RomeroR and MorG. (2014). New insights into the relationship between viral infection and pregnancy complications. Am J Reprod Immunol, 71:387–390.
23.
Arechavaleta-VelascoF, MaY, ZhangJ, McGrathCM and ParryS. (2006). Adeno-associated virus-2 (AAV-2) causes trophoblast dysfunction, and placental AAV-2 infection is associated with preeclampsia. Am J Pathol, 168:1951–1959.
24.
SilasiM, CardenasI, KwonJY, RacicotK, AldoP and MorG. (2015). Viral infections during pregnancy. Am J Reprod Immunol, 73:199–213.
25.
VerdecchiaP, CavalliniC, SpanevelloA and AngeliF. (2020). The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med, 76:14–20.
26.
HoffmannM, Kleine-WeberH, SchroederS, KrügerN, HerrlerT, ErichsenS, SchiergensTS, HerrlerG, WuN-H, et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 181:271–280.e8.
27.
PengR, WuLA, WangQ, QiJ and GaoGF. (2021). Cell entry by SARS-CoV-2. Trends Biochem Sci, 46:848–860.
28.
OuyangY, BagalkotT, FitzgeraldW, SadovskyE, ChuT, Martínez-MarchalA, Brieño-EnríquezM, SuEJ, MargolisL, SorkinA and SadovskyY. (2021). Term human placental trophoblasts express SARS-CoV-2 entry factors ACE2, TMPRSS2, and Furin. mSphere, 6:e00250-21.
29.
BloiseE, ZhangJ, NakpuJ, HamadaH, DunkCE, LiS, ImperioGE, NadeemL, KibschullM, et al. (2020). Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm. Am J Obstet Gynecol, 224:298.e1–e298.e8.
30.
OkaeH, TohH, SatoT, HiuraH, TakahashiS, ShiraneK, KabayamaY, SuyamaM, SasakiH and ArimaT. (2018). Derivation of human trophoblast stem cells. Cell Stem Cell, 22:50–63.e6.
LiaoY, SmythGK and ShiW. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 30:923–930.
33.
LoveMI, HuberW and Anders.S (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 15(12).
34.
ZhouY, ZhouB, PacheL, ChangM, KhodabakhshiAH, TanaseichukO, BennerC and ChandaSK. (2019). Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun, 10:1523.
35.
MoreyR, FarahO, KallolS, RequenaDF, MeadsM, Moretto-Zita MM, SoncinF, LaurentLC and ParastMM. (2021). Transcriptomic drivers of differentiation, maturation, and polyploidy in human extravillous trophoblast. Front Cell Dev Biol, 9:702046.
36.
Martín-VicenteM, MedranoLM, ResinoS, García-SastreA and MartínezI. (2017). TRIM25 in the regulation of the antiviral innate immunity. Front Immunol, 8:1187.
37.
VerhelstJ, HulpiauP and SaelensX. (2013). Mx proteins: antiviral gatekeepers that restrain the uninvited. Microbiol Mol Biol Rev, 77:551–566.
38.
DhillonB, AleithanF, Abdul-Sater and Abdul-SaterZ. (2019). The evolving role of TRAFs in mediating inflammatory responses. Front Immunol, 10:104.
39.
GiraldoMI, HageA, van TolS and RajsbaumR. (2020). TRIM proteins in host defense and viral pathogenesis. Curr Clin Microbiol Rep, 7:101–114.
40.
DiamondMS and KannegantiTD. (2022). Innate immunity: the first line of defense against SARS-CoV-2. Nat Immunol, 23:165–176.
41.
Parast MM. (2017). Chronic Villitis/Villitis of Unknown Etiology (VUE). In: Redline RW, TK Boyd TK and DJ Roberts eds. Placental and Gestational Pathology. Cambridge University Press: Cambridge;137–44.
42.
Lu-CulliganA and IwasakiA. (2020). The role of immune factors in shaping fetal neurodevelopment. Annu Rev Cell Dev Biol, 36:441–468.
43.
Nadeau-ValléeM, ObariD, PalaciosJ, MÈ Brien, DuvalC, ChemtobS and GirardS. (2016). Sterile inflammation and pregnancy complications: a review. Reproduction, 152:R277–R292.
44.
WeckmanAM, NgaiM, WrightJ, McDonaldCR and KainKC. (2019). The impact of infection in pregnancy on placental vascular development and adverse birth outcomes. Front Microbiol, 10:1924.
45.
YockeyLJ, LucasC and IwasakiA. (2020). Contributions of maternal and fetal antiviral immunity in congenital disease. Science, 368:608–612.
46.
ArguetaLB, LackoLA, BramY, TadaT, CarrauL, ZhangT, UhlS, LuborBC, ChandarV, et al. (2021). SARS-CoV-2 infects syncytiotrophoblast and activates inflammatory responses in the placenta. bioRxiv, 2021:446676.
47.
KarvasRM, KhanSA, VermaS, YinY, KulkarniD, DongC, Park-MiK, ChewB, SaneE, et al. (2022). Stem-cell-derived trophoblast organoids model human placental development and susceptibility to emerging pathogens. Cell Stem Cell, 29:810–825.e8.
48.
Schoggins JW. (2019). Interferon-stimulated genes: what do they all do?. Ann Rev Virol, 6:567–584.
49.
PrasadK, KhatoonF, RashidS, AliN, AlAsmariAF, AhmedMZ, AlqahtaniAS, AlqahtaniMS and KumarV. (2020). Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective. Int J Biol Macromol, 163:1–8.
50.
Prelli BozzoC, NchiouaR, VolcicM, KoepkeL, KrügerJ, SchützD, HellerS, StürzelCM, KmiecD, et al. (2021). IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Nat Commun, 12:1–13.
51.
JochemsSP, FerreiraDM and SmitsHH. (2021). ISG15 secretion exacerbates inflammation in SARS-CoV-2 infection. Nat Immunol, 22:1360–1362.
52.
AshleyCL, AbendrothA, McSharryBP and SlobedmanB. (2019). Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression. Viruses, 11:246.
53.
SchultzeJL and AschenbrennerAC. (2021). COVID-19 and the human innate immune system. Cell, 184:1671.
54.
ZieglerCGK, AllonSJ, NyquistSK, MbanoIM, MiaoVN, TzouanasCN, CaoY, YousifAS, BalsJ, et al. (2020). SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell, 181:1016.
55.
ChakrabortyC, SharmaAR, BhattacharyaM, ZayedH and LeeSS. (2021). Understanding gene expression and transcriptome profiling of COVID-19: an initiative towards the mapping of protective immunity genes against SARS-CoV-2 infection. Front Immunol, 12:1.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
